Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > How is this even possible in this market?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(26)
•••
Comment by Bucknelly21on Apr 22, 2021 3:02pm
64 Views
Post# 33046537

RE:RE:RE:RE:RE:How is this even possible in this market?

RE:RE:RE:RE:RE:How is this even possible in this market?
stockman75 wrote: FTV, do you really think confirmation of NASH moves anything? My guess is confirmation of the protocal doesn't even move the needle. I don't think anyone is paying attention to THTX except a very few. 

My guess. Only breakthrough cancer news starts to move this old horse....

Hope you are right though! 



FredTheVoice wrote: Said it before, and a couple of times in the last weeks....

No confirmation about NASH, no big mouvement around the stock.....

Nothing to do with management.....

FTV.


kinda agree and if that doesn't convince anyone that management isn't the issue I don't know what will 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities